Ohio drug startup focused on MRSA infection
from MedCity News
An Ohio University startup is developing a new antibacterial drug that would keep so-called "superbugs" such as MRSA from replicating in the body. Promiliad Biopharma is hoping its early development efforts yield a new drug capable of beating bacteria that have grown resistant to most antibiotics on the market. The most well-known example is a Methicillin-resistant Staphylococcus Aureus, or MRSA, infection.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063